Relapse prevention in adults with major depressive disorder treated with vilazodone

Abstract

Supplemental Digital Content is available in the text.

Effects of antidepressant medicines on preventing relapse of unipolar depression: a pooled analysis of parametric survival curves

“…Thirty-seven relevant RCTs were included in the predefined analysis (Amsterdam & Bodkin, 2006; Boulenger, Loft, & Florea, 2012; Coppen et al, 1978; Dalery, Dagens-Lafont, & De Bodinat, 2001; Davidson & Raft, 1984; Dobson et al, 2008; Durgam, Chen, Migliore, Prakash, & Thase, 2019; Durgam et al, 2018; Feiger et al, 1999; Gilaberte et al, 2001; Goodwin, Boyer, Emsley, Rouillon, & de Bodinat, 2013; Hochstrasser et al, 2001; Kamijima, Burt, Cohen, Arano, & Hamasaki, 2006; Kasper, Volz, Moller, Dienel, & Kieser, 2008; Keller et al, 1998, 2005; Kocsis et al, 2007; Liebowitz et al, 2010; McGrath et al, 2006; Montgomery & Dunbar, 1993; Montgomery et al, 1988; Montgomery, Entsuah, Hackett, Kunz, & Rudolph, 2004; Montgomery, Rasmussen, & Tanghoj, 1993; Perahia et al, 2006, 2009; Rickels et al, 2010; Robert & Montgomery, 1995; Robinson et al, 1991; Rosenthal, Boyer, Vialet, Hwang, & Tourian, 2013; Rouillon, Warner, Pezous, & Bisserbe, 2000; Shiovitz, Greenberg, Chen, Forero, & Gommoll, 2014; Simon, Aguiar, Kunz, & Lei, 2004; Terra & Montgomery, 1998; Thase, Nierenberg, Keller, Panagides, & Relapse Prevention Study, 2001; Versiani, Mehilane, Gaszner, & Arnaud-Castiglioni, 1999; Weihs et al, 2002). A flowchart of the screening process is presented in online Supplementary Appendix S2.…”

Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice

“…During the initial 20-week open treatment phase of the randomized relapse prevention trial, 8% of patients were discontinued from the study due to adverse effects, the most common of which were diarrhea, nausea and headache. 58 Most cases of diarrhea and nausea resolved within 2 weeks with ongoing treatment. 58 During the 28-week double-blind relapse-prevention phase, 3% of patients randomized to vilazodone 20 mg/day and 0.5% of patients randomized to vilazodone 40 mg/day or placebo dropped out owing to adverse effects.…”

“… 58 Most cases of diarrhea and nausea resolved within 2 weeks with ongoing treatment. 58 During the 28-week double-blind relapse-prevention phase, 3% of patients randomized to vilazodone 20 mg/day and 0.5% of patients randomized to vilazodone 40 mg/day or placebo dropped out owing to adverse effects.…”

“… 57 In a more rigorous randomized relapse prevention trial, 1204 adults with MDD received 20 weeks of open treatment with vilazodone 40 mg/day. 58 Of those, 564 patients achieved a positive response and were randomized to 28 weeks of double-blind treatment with one of the two fixed doses of vilazodone (20 mg/day or 40 mg/day) or placebo. During the double-blind treatment phase, crude rates of relapse, defined as a MADRS total score ≥18 and diagnostic criteria for a major depressive episode having been met, were similar between vilazodone 20 and 40 mg/day and placebo (11% vs 13% vs 13%, respectively).…”

“…Longer term safety data of vilazodone for MDD are from one 52-week single-arm trial and one 24-week randomized relapse prevention trial. 57 , 58 In the 52-week trial, the most frequent adverse effects with vilazodone were diarrhea (36%), nausea (32%), and headache (20%). For over 94% of cases, the severity of these adverse effects was mild to moderate.…”